Company intelligence / Profile preview

Modava

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

Modava is a South Korean biotechnology company focused on developing next-generation metabolic and endocrine therapies. The company specializes in the discovery and optimization of multi-agonist peptides targeting the GLP-1, GIP, and glucagon receptors to treat obesity and related metabolic disorders. By leveraging its proprietary peptide engineering platform, Modava aims to create highly potent and stable therapeutic candidates with improved safety profiles. The company's lead programs are currently in the pre-clinical stage, targeting significant unmet needs in the global metabolic disease market.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculePeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Modava.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Modava.

Explore the full profile